Download Ketamine for Treatment-Resistant Depression Ebook PDF

Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
The First Decade of Progress

by Sanjay J. Mathew,Carlos A. Zarate, Jr.

  • Publisher : Springer
  • Release : 2016-11-25
  • Pages : 155
  • ISBN : 3319429256
  • Language : En, Es, Fr & De
GET BOOK

This book brings together an international group of clinicians and researchers from a broad swath of inter-related disciplines to offer the most up-to-date information about clinical and preclinical research into ketamine and second-generation “ketamine-like” fast-acting antidepressants. Currently available antidepressant medications act through monoaminergic systems, are ineffective for many individuals suffering from depression, and are associated with a delayed onset of peak efficacy of several months. The unexpected emergence of ketamine, an anesthetic N-methyl-D-aspartate (NMDA) receptor antagonist, as a rapid-acting antidepressant has reinvigorated CNS drug discovery research and catalyzed investigation in patient populations historically ignored in antidepressant drug development programs, particularly treatment-resistant patients and those with suicidality. Recent industry and academic research efforts have coalesced to explore NMDA receptor and glutamatergic molecular targets that lack ketamine’s psychotomimetic side effects and abuse liability but retain its rapid onset of efficacy. However, many fundamental questions remain regarding the neurobiological mechanisms underlying ketamine’s rapid antidepressant effects and the puzzling persistence of benefits observed in some patients following a single dose. This book examines how insights from these studies are forging new conceptual models of the neurobiology of stress-related affective, anxiety, and addictive disorders and the nature of treatment resistance. It also discusses how ketamine’s rapid antidepressant effects provide a scientific platform to facilitate innovation in clinical trial designs pertaining to patient selection, choice of control group, outcome measures, and dose-optimization. This book brings together data and insights from this rapidly expanding and extraordinarily promising field of study. Readers will be able to extract integrated themes and useful insights from the material contained in these diverse chapters and appreciate the paradigm-shifting contributions of ketamine to modern psychiatry and clinical neuroscience research.

Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
Neurobiology and Applications

by Gustavo H. Vazquez,Carlos A. Zarate,Elisa Brietzke

  • Publisher : Academic Press
  • Release : 2020-10-15
  • Pages : 150
  • ISBN : 0128210338
  • Language : En, Es, Fr & De
GET BOOK

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action

Ketamine for Depression

Ketamine for Depression
A Book

by Dr. Stephen J. Hyde

  • Publisher : Xlibris Corporation
  • Release : 2015-09-04
  • Pages : 222
  • ISBN : 1503509532
  • Language : En, Es, Fr & De
GET BOOK

Given the unacceptably high rates of suffering, disability and premature death experienced by people with treatment-resistant depression and the surprisingly low rates of problems arising from the use of ketamine to treat the disorder, this is a therapy that all patients and their doctors should be discussing. This book summarises the research that has been carried out into ketamine for the treatment of depression over the past 15 years and, most importantly, describes different ways of using ketamine that are both practical and cost–effective. Currently most ketamine therapy is given intravenously in specialised clinics at considerable expense, but the author has successfully treated patients with low-dose sublingual ketamine and his patients have been able to safely take this at home. Profits from the sales of this book will assist further research into the use of ketamine for the treatment of depression.

11 - THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION

11 - THE USE OF SUBCUTANEOUS KETAMINE FOR TREATMENT-RESISTANT DEPRESSION
A Book

by Mariane Quieroti Rodrigues

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 129
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Introduction: Major depressive disorder is highly common with up to 50% to 60% of the patients not achieving adequate response following antidepressant treatment. In this scenario, ketamine emerges as an important alternative to conventional treatments, with its action of being an antagonist of N-methyl- D-aspartate (NMDA) receptor, once its has a quick and effective action. Ketamine is most frequently administered intravenous. However, oral, sublingual, transmucosal, intranasal, subcutaneous (SC), and intramuscular routes of administration have also been examined.Aim: This study aims to investigate whether SC ketamine is effective in the treatment of unipolar major depression and if it has more effective and sustainable response than electroconvulsivetherapy (ECT).Methods: Participants will be comprised of patients with unipolar depression resistant to conventional treatment, men and women, aged u2265 18 across a range of ethnicities, recruited from General Hospital Servidor of State of Su00e3o Paulo, Brazil. Participants will be separeted in two groups. The first one will recieve a SC administration of ketamine in the dose of 0,5mg/kg weekly, for 6 weeks. The second will be submitted to ECT treatment, two sessions a week, for at least 8 sessions. The response of each treatment will be evaluated and compared by MADRS questionnaire.Results: We expect that SC ketamine has a good response in the treatment of major depression and that it has a similar response compared to ECT.Conclusion: SC ketamine, once it is a secure, quick and simple procedure, is a promising alternative to the available treatments.

Ketamine for Treatment Resistant Depression Or Post-Traumatic Stress Disorder in Various Settings

Ketamine for Treatment Resistant Depression Or Post-Traumatic Stress Disorder in Various Settings
A Review of Clinical Effectiveness, Safety, and Guidelines

by Joanne Kim

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 30
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

05 - KETAMINE ANTIDEPRESSANT ACTIONS IN ELECTROCONVULSIVE THERAPY OF TREATMENT-RESISTANT DEPRESSION

05 - KETAMINE ANTIDEPRESSANT ACTIONS IN ELECTROCONVULSIVE THERAPY OF TREATMENT-RESISTANT DEPRESSION
A Book

by Bruno Josu00e9 Prates

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 129
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Background and aims: Major depressive disorder affects approximately 5% of the population with nearly 1-third of patients failing to achieve remission, despite adequate pharmacological treatment [1]. Although electroconvulsive therapy (ECT) is the gold standard approach for treatment resistant depression (TRD), a considerable fraction of patients also show a delayed improvement or appear to be resistant to ECT. One of the most promising rapid-acting antidepressants is ketamine, a noncompetitive N-methyl-D-Aspartate receptor antagonist that can be used as an anesthetic during ECT to augment antidepressant efficacy [2].Data on ECTs using ketamine are both scarce and conflicting which lead the American Psychiatric Association to call for further studies [3]. We aim to clarify the potential synergism of ketamine and ECT for the treatment of TRD.Materials and methods: An experimental, non-randomized clinical trial with consecutive sampling of TRD patients with a HAM-D and PDAS scores u2265 23 was conducted. Patients that were initially assigned to 6 ECT sessions using thiopental anesthesia (ECT Std) but showed a very limited symptomatic relief were included in the study. Patients in Group 1 were then treated with further 6 ECT sessions using ketamine anesthesia (ECT Ket) whereas Group 2 maintained treatment with ECT Std (Fig. 1).Results: Clinical assessment showed no significant reduction in the mean HAM-D and PDAS scores for Group 1 but a significant reduction of the HAMD score of 38,8u00b12,4 to 13.4u00b110.55 (p

Ketamine

Ketamine
From Abused Drug to Rapid-Acting Antidepressant

by Kenji Hashimoto,Soichiro Ide,Kazutaka Ikeda

  • Publisher : Springer Nature
  • Release : 2020-03-05
  • Pages : 189
  • ISBN : 9811529027
  • Language : En, Es, Fr & De
GET BOOK

This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants.

IV Ketamine Infusion Therapy for Depression

IV Ketamine Infusion Therapy for Depression
Why I Tried It, What It's Like, and If It Worked

by Frank Ligons

  • Publisher : Unknown Publisher
  • Release : 2021-04-15
  • Pages : 118
  • ISBN : 9781736892510
  • Language : En, Es, Fr & De
GET BOOK

Many depressed patients are "treatment-resistant," unable to find relief. Ketamine Infusions help TWO-THIRDS of these cases.

Ready, Set, Action: Potential Breakthrough Therapy for Treatment-Resistant Depression

Ready, Set, Action: Potential Breakthrough Therapy for Treatment-Resistant Depression
A Book

by Alvin Garlejo

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 129
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Major depressive disorder is a psychiatric illness that is associated with a variety of debilitating symptoms such as persistent sadness, lack of interest and motivation, lassitude, pessimistic thoughts, and in severe cases, suicidal ideation and behavior. Current psychological and pharmacological treatments have been demonstrated efficacious; however, an ever-growing number of individuals frequently report minimal to no improvement with these treatments; and in some cases, a worsening of symptoms. This inadequacy to treatment is commonly known as treatment-resistant depression. At Kadima Neuropsychiatry Institute, Dr. Feifel treats individuals with treatment-resistant depression with advanced treatments such as TMS and ketamine. During my fieldwork internship at Kadima Neuropsychiatry Institute, my project focused on evaluating the efficacy of ketamine administered intramuscular to patients with treatment-resistant depression and determining which characteristics of a patient0́9s psychedelic experience or 0́−trip0́+ is associated with the decrease in their depressive symptoms. The results of this project demonstrated that an initial low dose of ketamine was significantly quick and efficacious in decreasing depressive symptoms in patients with treatment resistant depressive. In addition, a first of its kind exploratory analysis suggested that the intensity, positive content, and dissociative characteristics of a ketamine induced psychedelic trip were strongly associated with the decrease in depressive symptoms. Despite the significance in these results, more research needs to include a larger sample and explore the specific subjective characteristics within a psychedelic 0́−trip0́+ to further understand its association with a decrease in depressive symptoms. The quick and efficacious antidepressant effects of ketamine demonstrated in this project provide much potential for a program involving a mobile ketamine clinic to address severe depression and suicidality. Such therapeutic and intervention potentials can be explored further given an expansion of current policy limiting ketamine as a schedule III substance.

Intravenous Ketamine for Adults with Treatment-Resistant Depression Or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines

Intravenous Ketamine for Adults with Treatment-Resistant Depression Or Post-Traumatic Stress Disorder: A Review of Clinical Effectiveness, Cost-Effectiveness and Guidelines
A Book

by Anonim

  • Publisher : Unknown Publisher
  • Release : 2019
  • Pages : 129
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Ketamine for Treatment-Resistant Depression

Ketamine for Treatment-Resistant Depression
Neurobiology and Applications

by Gustavo H. Vazquez,Carlos A. Zarate,Elisa Brietzke

  • Publisher : Academic Press
  • Release : 2020-10-01
  • Pages : 168
  • ISBN : 0128210346
  • Language : En, Es, Fr & De
GET BOOK

Ketamine for Treatment-Resistant Depression: Neurobiology and Applications provides a simple, evidence-based overview for neuropsychiatrists and translational researchers on this medication, its mechanisms of actions, eligibility of patients for treatment, and the preparation and implementation of ketamine clinics. Provides efficacy research on ketamine as a treatment for depression Identifies best practices for clinical use, both long-term and acute Discusses the molecular mechanisms and neurobiology of action

Intravenous Ketamine Therapy in a Patient with a Treatment-resistant Major Depression

Intravenous Ketamine Therapy in a Patient with a Treatment-resistant Major Depression
A Book

by Michael Liebrenz

  • Publisher : Unknown Publisher
  • Release : 2007
  • Pages : 52
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Intravenous Ketamine for Treatment of Major Depressive Disorder in a Patient with a History of Repetitive Traumatic Brain Injuries

Intravenous Ketamine for Treatment of Major Depressive Disorder in a Patient with a History of Repetitive Traumatic Brain Injuries
A Book

by John William III

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 129
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

INTRODUCTION: Depression is the most common psychiatric disorder that occurs following a Traumatic Brain Injury. To date, there are limited studies demonstrating the effectiveness of current treatments for this disorder and even less for those with repetitive injuries or rTBIs. Ketamine has been demonstrated to be effective in successfully treating depression and helping with damaged connectivity within the brain. It can be hypothesized that Ketamine may help with both of these areas that many TBI patients face after injury. This particular case report describes the successful treatment of a patient with a history of rTBIs who struggled with depression for the past several years. CASE PRESENTATION: Mr. M is as 51 year old single caucasian male who presented to the Actify Neurotherapies Treatment Center for treatment of his Major Depressive Disorder. He had been depressed for five years but refused oral medication treatment due to fears over side effects. He presented with anergia, amotivation, feelings of sadness, anhedonia, impaired concentration and guilt/worthlessness with a QIDS score of 20 (Severe Depression) and GAD-7 of 18 (Severe Anxiety). Previous neuropsychological records revealed some cognitive impairment likely attributed to his multiple head injuries which included being hit over the head in an alley leading to amnesia for one month along with permanent anosmia. After completing a course of five Ketamine treatments, his symptoms either completely resolved or vastly improved as measured by the Levine Treatment Resistant Depression Scale (LRDTS). CONCLUSION: This case appears to be the first published report of a patient with multiple TBIs/rTBIs and Major depressive disorder successfully treated with intravenous ketamine. Overall, this illustrates the potential role that Ketamine may play in the treatment of psychiatric sequelae in individuals with a history of rTBIs. Ketamine has been demonstrated to increase BDNF and increase synaptogenesis which should encourage further research for brain injured individuals. Ketamine is also believed to potentially have neuroprotective effects as well which need to be further studied. Those with a history of one TBI are also at increased risk of having further rTBIs and therefore further increasing the chances of a depressive disorder. If one might be able to treat the individual before the repetitive event occurs, it may lead to quicker resolution of symptoms and may even decrease the chances of a subsequent event from occurring. Further studies are necessary to validate and replicate the symptom resolution of the above case but indicates that this treatment may be a potential viable rapid treatment option for those struggling without relief in sight.

Effect of Ketamine Treatment on Neuronal Oscillatory Activity in the Nucleus Accumbens and Hippocampus in an Animal Model of Treatment-Resistant Depression

Effect of Ketamine Treatment on Neuronal Oscillatory Activity in the Nucleus Accumbens and Hippocampus in an Animal Model of Treatment-Resistant Depression
A Book

by Duncan Rasmussen

  • Publisher : Unknown Publisher
  • Release : 2020
  • Pages : 129
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Depression is a globally prevalent disorder characterized by negative symptoms including amotivation and suicidality. Ketamine is a treatment that can provide rapid, long-lasting antidepressant effects, but also exhibits harsh psychomimetic side effects that greatly hinder its accessibility and tolerability. Macroscopic neuronal oscillations are essential for communication within the brain and are dysregulated in several neuropsychiatric disorders including depression. This study therefore used the Wistar-Kyoto (WKY) animal model of treatment resistant depression to examine the effects of ketamine on neural oscillatory activity in two brain regions implicated in the pathophysiology of depression, the nucleus accumbens (NAc) and hippocampus (HIP). At baseline, WKY males showed abnormalities in delta and theta power in the NAc and HIP, but not NAc-HIP coherence. Female WKY rats showed similar abnormalities in HIP, but not NAc, and increased NAc-HIP theta coherence. Ketamine administration normalized the dysfunction in NAc of males and theta coherence between NAc-HIP in females.

EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT‐RESISTANT DEPRESSION.

EFFECTS OF KETAMINE ON EXPLICIT AND IMPLICIT SUICIDAL COGNITION: A RANDOMIZED CONTROLLED TRIAL IN TREATMENT‐RESISTANT DEPRESSION.
A Book

by Anonim

  • Publisher : Unknown Publisher
  • Release : 2014
  • Pages : 129
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Ketamine

Ketamine
From Abused Drug to Rapid-acting Antidepressant

by Anonim

  • Publisher : Unknown Publisher
  • Release : 2020
  • Pages : 187
  • ISBN : 9789811529030
  • Language : En, Es, Fr & De
GET BOOK

This book presents the latest data from basic research and clinical trials supporting the effectiveness of ketamine as a treatment for depression, bipolar disorder, and suicidal behavior, setting these positive findings within the context of the serious problem of ketamine abuse. The first part of the book focuses on the evidence regarding ketamine abuse, with specific reference to Asian countries, and discusses countermeasures and complication management. It then addresses the mechanisms underlying the antidepressant and side effects of ketamine, which have remained elusive, describing and discussing important new research findings. Further, it explains insights gained from whole brain imaging in rodents and from behavioral pharmacology, and presents evidence regarding the role of gut microbiota, the NMDA receptor GluN2D subunit, and the lateral habenula in the actions of ketamine. These advances form the basis for the safer use of ketamine in patients with treatment-resistant depression and are expected to lead to the development of new antidepressants. --

Managing Treatment-Resistant Depression

Managing Treatment-Resistant Depression
A Book

by Joao Quevedo,Patricio Riva Posse,William V. Bobo

  • Publisher : Academic Press
  • Release : 2022-01-15
  • Pages : 820
  • ISBN : 9780128240670
  • Language : En, Es, Fr & De
GET BOOK

Many depressed patients are not able to achieve or sustain symptom remission despite participating in serial treatment trials. This is often termed "treatment-resistant depression (TRD)”. Managing Treatment-Resistant Depression: Road to Novel Therapeutics first defines TRD for readers, discussing the clinical and epidemiological predictors, economic burden and neurobiological factors. Staging methods for treatment resistance are fully covered in this book, including serotonin specific reuptake inhibitors, serotonin norepinephrine reuptake inhibitors, other classes of antidepressants, including tricyclic antidepressants and monoamine oxidase inhibitors, augmentation strategies, and newer antidepressant treatments like ketamine and esketamine. In addition, evidence supporting use of psychotherapies, and neuromodulation strategies are also reviewed. Written by top experts in the field, this book is the first of its kind to review all methods of treatment for TRD. Defines Treatment-Resistant Depression and Staging Treatment Intensity Includes Treatment-Resistant Depression options for children, adolescents, geriatric, pregnancy, post-partum, and during menopause transitions Discusses the use of Ketamine and Esketamine for treatment-resistant depression

Ketafusion, LLC

Ketafusion, LLC
A Book

by Doris Tarrillion

  • Publisher : Unknown Publisher
  • Release : 2019
  • Pages : 59
  • ISBN : 9781088322253
  • Language : En, Es, Fr & De
GET BOOK

Abstract: Depression is a debilitating and devastating mood disorder that can affect all ages and people of all races across all socioeconomic statuses. Conventional antidepressant medications only give one-third of relief from symptoms of depression, leaving the remainder to suffer from treatment-resistant depression (TRD). For the past two decades, researchers have looked into ketamine for the treatment of depression with promising results. All studies have validated that the intravenous (IV) use of ketamine is now the breakthrough treatment for TRD. This creates demand and a dire need to those are suffering from treatment-resistant depression. Ketafusion, LLC will specialize in delivery of safe and affordable intravenous ketamine infusion in the heart of Los Angeles County. It will provide personalized concierge care throughout every step of the treatment and recovery process to improve the quality of life of individuals battling TRD.

07 - KYNURENINE PATHWAY AS A TARGET AND BIOMARKER OF THE ANTIDEPRESSANT EFFECT OF KETAMINE

07 - KYNURENINE PATHWAY AS A TARGET AND BIOMARKER OF THE ANTIDEPRESSANT EFFECT OF KETAMINE
A Book

by Fabien Vinckier

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 129
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

IntroductionIn recent decades, comprehensive evidence has accumulated that inflammation might be implied in the etiology of major depressive disorder besides monoamine imbalance classically described. In inflammatory conditions, the degradation of tryptophan is prioritized towards the production of kynurenine, leading to the production by microglial cells of quinolinic acid (QUIN), an excitotoxic NMDA receptor agonist. Ketamine is then a very promising antidepressant, and its NMDA antagonism might counteract QUIN accumulation. ObjectivesIn this study, the immune-modulating capacities of ketamine was investigated in depressed patients by examining the effect of ketamine treatment on tryptophan metabolites plasma levels. Methods15 treatment-resistant depressed in-patients received a cure of ketamine infusions (0.5 mg/kg intravenously), one or two times per week. Before and after each infusion, depression severity was assessed with the MADRS and plasma levels of tryptophan, kynurenine, kynurenic acid (KYNA), and QUIN were measured by HPLC and mass spectrometry. ResultsWe observed that pre-treatment KYNA/QUIN is a predictor of MADRS score after a ketamine infusion and after a whole cure of ketamine independently to depression severity (beta=0.28u00b10.07, p=0.0002 and beta=1.05u00b10.35, p=0.016 respectively). The variation of QUIN after a ketamine infusion is also a predictor of the percentage of variation in MADRS score after a ketamine infusion (beta=0.35u00b10.14, p=0.015). ConclusionsKetamine acts not only by counteracting QUIN on NMDA receptors but by reducing its production. As the tryptophan metabolism pathway is mainly supported by microglia in the brain, these findings underpin the immune-modulatory capacity of ketamine, suggesting microglia as a key therapeutic target and QUIN as a biomarker of ketamine response.

Development and Validation of an Animal Model of Treatment Resistant Depression

Development and Validation of an Animal Model of Treatment Resistant Depression
A Book

by Sarel Jacobus Brand

  • Publisher : Unknown Publisher
  • Release : 2017
  • Pages : 373
  • ISBN : 9876543210XXX
  • Language : En, Es, Fr & De
GET BOOK

Biomarkers -- Depression -- FSL -- Gene-environment -- Imipramine -- Ketamine -- Noradrenalin -- PTSD -- Serotonin -- Treatment resistance -- Venlafaxine -- Behandelingsweerstandigheid -- Biomerkers -- Depressie -- Geen-omgewing -- Imipramien -- Ketamien -- PTSV -- Venlafaksien.